In the future, it will be of interest to examine the effect of gemcitabine treatment on MUC4-expressing and non-expressing pancreatic cancer cell lines in vivo to support the pathogenic relevance of MUC4 with the acquisition of resistance to chemotherapeutics. This evidence concerns the gene MUC4 and familial pancreatic carcinoma.